TCGA-DK-AA6Q-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.56767411
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.420
- MYC_TARGETS_V2+0.390
- G2M_CHECKPOINT+0.360
- INTERFERON_GAMMA_RESPONSE+0.360
- MTORC1_SIGNALING+0.350
- APICAL_SURFACE+0.340
- MYC_TARGETS_V1+0.310
- E2F_TARGETS+0.300
- ALLOGRAFT_REJECTION+0.290
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- ANGIOGENESIS-0.230
- KRAS_SIGNALING_UP-0.200
- MYOGENESIS-0.160
- PROTEIN_SECRETION-0.140
- UV_RESPONSE_DN-0.140
- ADIPOGENESIS-0.080
- COAGULATION-0.080
- HYPOXIA-0.080
- APOPTOSIS-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-66-2794-01A-01R-1201-07 | — | cohortSQ2 | 0.845 |
| 2 | TCGA-18-3416-01A-01R-0980-07 | — | cohortSQ2 | 0.796 |
| 3 | ERR2278873 | — | — | 0.789 |
| 4 | TCGA-CV-7089-01A-11R-2016-07 | — | — | 0.786 |
| 5 | TCGA-33-4583-01A-01R-1443-07 | — | cohortSQ2 | 0.784 |
| 6 | 4fc05c1a-63b9-415b-ad42-68b013e21b21 | — | — | 0.778 |
| 7 | TCGA-K4-A4AC-01A-21R-A26T-07 | — | — | 0.775 |
| 8 | SRR8518159 | — | E | 0.773 |
| 9 | TCGA-E7-A7XN-01A-11R-A352-07 | — | — | 0.770 |
| 10 | MNG921 | — | — | 0.769 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.340 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.240 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |